Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer

Deepali Sachdev

Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer

Curr Opin Mol Ther. 2007 Jun;9(3):299-304.

Author

Deepali Sachdev¹

Affiliation

¹ Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA. sachd003@umn.edu

PMID: 17608029

Abstract

Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC, a phase II trial of CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected]

MeSH terms

Antibodies / adverse effects
Antibodies / immunology
Antibodies / therapeutic use*
Carboplatin / therapeutic use
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Drug Evaluation, Preclinical
Humans
Neoplasms / drug therapy*
Paclitaxel / therapeutic use
Receptors, Somatomedin / immunology*

Substances

Antibodies
Receptors, Somatomedin
Carboplatin
Paclitaxel